The role of targeted therapy and biomarkers in breast cancer treatment

Alison T. Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, Ben Ho Park, Sara E. Barnato, William J. Gradishar, Clifford A. Hudis, Hope S. Rugo

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

Original languageEnglish (US)
Pages (from-to)807-819
Number of pages13
JournalClinical and Experimental Metastasis
Issue number7
StatePublished - Oct 2012


  • Angiogenesis
  • Biomarkers
  • Breast cancer
  • Chemotherapy
  • Her2
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'The role of targeted therapy and biomarkers in breast cancer treatment'. Together they form a unique fingerprint.

Cite this